Journal
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
Volume 99, Issue 1, Pages 1-11Publisher
WILEY
DOI: 10.1111/j.1742-7843.2006.pto_352.x
Keywords
-
Categories
Ask authors/readers for more resources
For both type 1 and type 2 diabetes, tight glycaemic control is vital to reduce the risk of long-term complications. However, this must be achieved with minimal risk of hypoglycaemia. Glargine is a new long-acting insulin analogue with an action profile designed to overcome this and has now been in clinical use for a number of years. In many countries glargine is widely used. Here we present an update on the clinical information available on glargine with respect to glycaemic control, the risk of hypoglycaemia and quality of life in both type 1 and type 2 diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available